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Iowa
Board of Pharmacy
Reminder Regarding Pharmacist CE 
Requirements
Pharmacists are reminded that in addition to 15 hours of Ac-
creditation Council for Pharmacy Education (ACPE)-accredited 
drug therapy courses, they must now complete two hours of 
continuing education (CE) in pharmacy law and two hours of 
CE in patient or medication safety every two years (reference 
Rule 657, Iowa Administrative Code 2.12). 
A total of 30 hours of CE every two years remains the mini-
mum requirement for pharmacist license renewal.
To locate CE courses, pharmacists may check the P.L.A.N. 
Web site at https://www.acpe-accredit.org/pharmacists/ 
programs.asp. Pharmacists should click on “Search P.L.A.N.® 
Now” to open the search page. They can then select their search 
options and click “Search.”  
The CE in pharmacy law must be ACPE accredited. The CE 
inpatient/medication safety may be either ACPE accredited or 
non-ACPE accredited. Non-ACPE accredited provider activities 
must be provided by an accredited health professional continu-
ing education provider, such as a continuing medical education 
provider, and the activity content must directly relate to the 
pharmacist’s professional practice.
 ♦ ACPE course identifiers in pharmacy law for pharmacists 
end with “L03-P.”
 ♦ ACPE course identifiers in patient/medication safety for 
pharmacists end with “L05-P.”
New Patient Safety Task Force
In collaboration with the Iowa Pharmacy Association (IPA), 
the Iowa Board of Pharmacy is pleased to announce the forma-
tion of a new Patient Safety Task Force. The task force will be 
charged with creating a dialogue around the issue of patient 
safety and pharmacy work environments. The issue of patient 
safety is a key priority for both the Board and IPA. It crosses 
all pharmacy practice settings, including acute care, long-term 
care, community, and hospital. Issues will be addressed by 
stakeholders from all settings at both the practice level and the 
management level. The task force will meet as two subgroups 
throughout 2012 and will formulate recommendations to be 
presented in early 2013. The first meeting of the task force is 
scheduled for June 5, 2012. 
Board Member Retires
Pharmacist member Mark M. Anliker, 
RPh, of Emmetsburg, IA, retired from the 
Board on April 30, 2012. He served one 
three-year term, beginning on May 1, 2009. 
While on the Board, Mark also served on 
the Board’s Rules Committee. 
The Board extends its sincere thanks to 
Mark for his many contributions and his 
dedicated public service.
Board Member Reappointed
Congratulations to pharmacist member Susan M. Frey, 
RPh, of Villisca, IA, who was reappointed by Governor Terry 
Branstad to her third three-year term on the Board effective 
May 2, 2012. Sue is employed by Hy-Vee Pharmacy in Red 
Oak, IA, and also serves as a consultant pharmacist for several 
long-term care facilities. 
New Board Member Appointed
Congratulations to pharmacist Edward 
J. McKenna, RPh, of Storm Lake, IA, 
who was appointed to a three-year term on 
the Iowa Board of Pharmacy by Governor 
Branstad effective May 1, 2012. Ed is a 1969 
graduate of Creighton University School of 
Pharmacy and Health Professions. After 
owning and operating Lake Apothecary 
in Storm Lake for many years, Ed became 
a pharmacy manager for Hy-Vee in Storm 
Lake. He currently serves as president of 
the Storm Lake Board of Education. Ed replaces Mark Anliker 
on the Iowa Board of Pharmacy. The Board welcomes Ed and 
looks forward to working with him.
Election of Board Officers
The Board has reelected Susan Frey as Board chairperson for 
a one-year term beginning May 1, 2012. DeeAnn Wedemeyer-
Oleson, PharmD, RPh, was elected as vice chairperson for the 
same term.
in medication appearance. So much so that patients may not question a 
change or, when they do, practitioners may simply reassure them that 
it was due to a change in manufacturer without actively investigating 
the reason. It is not uncommon for ISMP to receive reports from both 
practitioners and consumers where a change in medication appearance 
was not fully investigated and subsequently contributed to an error.
In one case, a man shared an account of what his 86-year-old father 
experienced over the course of nine days after his prescription for mi-
noxidil was mistakenly refilled with another medication. He had been 
taking minoxidil 2.5 mg for years at a dose of 5 mg (2 tablets) twice 
daily. Due to failing vision, he did not realize that his minoxidil tablets 
looked different. His daughter noticed the change, but was unconcerned 
since the tablets had previously changed appearance. The pharmacy was 
contacted about the change and a staff member explained that it was a 
different generic for minoxidil, and that the pills could be exchanged 
for those that he usually received. There was no mention of a mistake 
being made when the medication was exchanged. He was taken to the 
hospital the following day, when he could barely walk.
After this incident was explained to hospital staff, they contacted 
the pharmacy. It was then revealed that he was given methotrexate by 
mistake because the bottles were stored next to each other. By this time, 
the man had taken 36 methotrexate 2.5 mg tablets, his white blood cell 
and platelet counts were extremely low, and he was in critical condition. 
We later learned that he passed away during that hospital visit.
Your pharmacy may be providing an important patient safety tool on 
the prescription label that may be overlooked by patients and their care-
givers: a description of the shape, color, and imprint code of the medica-
tion that should be inside. This information can help ensure accuracy since 
it’s based on the NDC number. Teach patients to look for this description 
and question any 
differences. In ad-
dition, the patient 
needs to know if the 
medication name 
on the pharmacy 
generated label 
is the medication 
he or she was ex-
pecting to receive. 
Even if the generic 
manufacturer is 
different each time 
the prescription is 
renewed, the de-
scription on the la-
bel should match 
the NDC number 
and thus the product 
inside.
FDA Reminder: Purchasing Unapproved Injectable 
Cancer Medications Threatens Patient Safety
FDA is reminding health care providers to obtain and use only FDA-
approved injectable cancer medications purchased directly from the 
manufacturer or from wholesale distributors licensed in the United States. 
FDA explains that “current shortages of injectable cancer medications 
may present an opportunity for unscrupulous individuals to introduce 
non-FDA approved products into the drug supply, which could result in 
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DEA Provides Information Regarding 
Carisoprodol Prescriptions 
A Drug Enforcement Administration (DEA) announcement provides 
information regarding the scheduling of carisoprodol, effective as of 
January 11, 2012. The DEA Final Rule making the drug a Schedule IV 
controlled substance was published December 12, 2011, and states that 
effective January 11, 2012, all prescriptions for drugs containing cari-
soprodol shall comply with DEA regulations. Specifically, a pharmacy 
may only fill or refill a prescription for a drug containing carisoprodol 
if all of the following requirements are met:
 ♦ the prescription was issued for a legitimate medical purpose by a 
DEA-registered practitioner acting in the usual course of professional 
practice (21 CFR §1306.04);
 ♦ the prescription contains all the information required by 21 CFR 
§1306.05; and
 ♦ the number of refills authorized by the prescribing practitioner is five 
or less (21 USC §829(b)).
The full text of the notice is available on the DEA Web site at  www 
.deadiversion.usdoj.gov/drugs_concern/carisoprodol/index.html.
Pfizer Recalls Several Lots of Two Oral 
Contraceptive Products 
Pfizer Inc recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl 
estradiol) tablets and 14 lots of norgestrel and ethinyl estradiol tablets 
(generic) due to potential for inexact count and out-of-sequence tablets. A 
Pfizer investigation found that some blister packs of the affected products 
may contain an inexact count of inert or active ingredient tablets and 
that the tablets may be out of sequence. As a result of this packaging 
error, the daily regimen for these oral contraceptives may be incorrect 
and could leave women without adequate contraception, and at risk for 
unintended pregnancy. Food and Drug Administration (FDA)  advises 
that patients who have the affected product should notify their physician 
and return the product to the pharmacy. A Pfizer press release includes a 
list of the affected products with the National Drug Code (NDC) number, 
lot number, and expiration date for each, and is available at www.fda.
gov/Safety/Recalls/ucm289770.htm.
Changes in Medication Appearance Should Prompt 
Investigation by Pharmacists and Patients
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and 
potentially hazardous conditions as reported 
by pharmacists and other practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gathers expert opinion about 
prevention measures, and publishes its recommendations. To read about 
the risk reduction strategies that you can put into practice today, sub-
scribe to ISMP Medication Safety Alert!® Community/Ambulatory Care 
Edition by visiting www.ismp.org. ISMP is a federally certified patient 
safety organization, providing legal protection and confidentiality for 
submitted patient safety data and error reports. ISMP is also an FDA 
MedWatch partner. Call 1-800/FAIL-SAF(E) to report medication errors 
to the ISMP Medication Errors Reporting Program or report online at 
www.ismp.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, 
PA 19044. Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
As the numbers of generic products continue to increase, it seems 
that both patients and practitioners have become desensitized to changes 
With so much information on prescription labels 
such as patient and doctor name, drug name, 
instructions, and warnings – this added information 
can easily be missed. But it’s important, so look for 
it and put it to use!
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serious harm to patients.” FDA reports that the agency is aware of pro-
motions and sales of unapproved injectable cancer medications directly 
to clinics in the US and that the medications were likely administered to 
patients. Examples of products include unapproved versions of FDA-
approved medications such as Faslodex® (fulvestrant), Neupogen® 
(filgrastim), Rituxan® (rituximab), and Herceptin® (trastuzumab). FDA 
stresses the risks to patients when such unapproved medications are used. 
The agency outlines several steps health care providers should take to 
ensure patient safety:
1. Obtain and use only FDA-approved injectable cancer medications 
purchased directly from the manufacturer or from wholesale distrib-
utors licensed in the US. An FDA Web page, www.fda.gov/Drugs/
DrugSafety/DrugIntegrityandSupplyChainSecurity/ucm281446 
.htm,  provides the online resource for each state for verifying that 
a wholesale distributor is appropriately licensed.
2. Determine if the medication you have received is FDA-approved by 
checking the Orange Book or searching the Drugs@FDA database.
3. Question whether a price sounds too good to be true. Deep discounts 
may be offered because the product is stolen, counterfeit, or unap-
proved.
4. Carefully inspect the product and packaging and be alert for signs 
that the product is not FDA approved, such as if the packaging looks 
different or the dosing recommendations are unfamiliar.
FDA also notes that if a health care provider receives multiple 
complaints about the same product, such as a new side effect or lack of 
therapeutic effect, these may signal a product quality issue. 
FDA reminds health care providers that in certain circumstances the 
agency may authorize limited importation of medications that are in 
short supply. Such medications are imported from approved interna-
tional sources and distributed in the US through a controlled network, 
and would not be sold in direct-to-clinic solicitations. If FDA has ar-
ranged for limited importation of the foreign version of a medication, 
information on obtaining that medication will be available in the Drug 
Shortages section of the FDA Web site, www.fda.gov/Drugs/DrugSafety/
DrugShortages/ucm050792.htm. 
Additional details are provided in an FDA Drug Safety Communi-
cation, available at  www.fda.gov/downloads/Drugs/DrugSafety/Drug 
IntegrityandSupplyChainSecurity/UCM287717.pdf.
Insulin Pens Should Not Be Used for Multiple 
Patients, Stresses CDC 
Centers for Disease Control and Prevention (CDC) issued a notice, 
reminding health care providers that insulin pens are intended for use 
by a single patient, and should never be used on more than one patient. 
CDC indicates that the agency has become “increasingly aware of 
reports of improper use of insulin pens, which places individuals at 
risk of infection with pathogens including hepatitis viruses and human 
immunodeficiency virus (HIV).” The notice explains that regurgitation 
of blood into the insulin cartridge can occur after injection, creating a 
risk of bloodborne pathogen transmission if the pen is used for more 
than one person, even when the needle is changed. CDC provides the 
following recommendations to help protect patient safety:
 ♦ Insulin pens containing multiple doses of insulin are meant for use 
on a single person only, and should never be used for more than one 
person, even when the needle is changed.
 ♦ Insulin pens should be clearly labeled with the person’s name or other 
identifying information to ensure that the correct pen is used only on 
the correct individual.
 ♦ Hospitals and other facilities should review their policies and educate 
their staff regarding safe use of insulin pens and similar devices.
 ♦ If reuse is identified, exposed persons should be promptly notified and 
offered appropriate follow-up including bloodborne pathogen testing.
The notice may be downloaded from the CDC Web site at www.cdc 
.gov/injectionsafety/PDF/Clinical-Reminder-insulin-pen.pdf.
US Public Health Service Report Supports 
Maximizing the Scope of the Pharmacist as Part 
of Health Care Team 
Presenting an evidence-based discussion of the comprehensive patient 
care services that pharmacists currently provide, a new government 
report calls for expanded support for such pharmacist-delivered patient 
care models. The report, Improving Patient and Health System Outcomes 
through Advanced Pharmacy Practice, prepared by the Office of the 
Chief Pharmacist, US Public Health Service (PHS), is organized into 
four focus points as follows:
 ♦ Focus point 1 discusses how pharmacists are integrated in many 
practice settings as health care providers, such as through collabora-
tive practice agreements, and provides data showing interprofessional 
support for such models.
 ♦ Focus points 2 and 3 support recognition of pharmacists as health 
care providers and compensation models that will allow pharmacists 
to continue to improve patient and health care system outcomes.
 ♦ Focus point 4 presents a review of numerous peer-reviewed studies 
that demonstrate favorable outcomes from pharmacist-delivered care.
RADM Scott Giberson, chief professional officer, PHS Pharma-
cists, and the primary author of the report, stated that “one of the most 
evidence-based and cost-effective decisions we can make as a nation 
is to maximize the expertise and scope of pharmacists, and minimize 
expansion barriers to successful health care delivery models.” The 
report may be downloaded from the US PHS Web site at  www.usphs 
.gov/corpslinks/pharmacy/comms/pdf/2011AdvancedPharmacy 
PracticeReporttotheUSSG.pdf.
 
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile Today!
CPE Monitor™ integration is underway. Soon all Accreditation 
Council for Pharmacy Education (ACPE)-accredited providers will 
require you to submit your NABP e-Profile ID, assigned when you 
set up your NABP e-Profile, along with your date of birth (MMDD), 
in order to obtain continuing pharmacy education (CPE) credit for 
any ACPE-accredited activity. Many have already begun to do so.
Visit www.MyCPEmonitor.net to set up your e-Profile and avoid 
possible delays in your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
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New Board Compliance Officer
Sue Mears, RPh, of Urbandale, IA, be-
gan employment with the Board as a com-
pliance officer on February 3, 2012. Sue 
is a graduate of Drake University College 
of Pharmacy and Health Sciences. Before 
joining the Board’s staff, she worked as a 
pharmacist for 16 years in various practice 
settings including community pharmacy, 
mail order, and long-term care. Sue cur-
rently serves the Central Iowa area. She 
receives e-mail at Sue.Mears@iowa.gov. 
Board Clarification on Manufacturer’s 
Coupons for Controlled Substances
At their meeting on April 27, 2012, the Board reviewed the 
rule regarding advertising prescription drug information by 
a pharmacy (reference Rule 657, Iowa Administrative Code 
8.12). Because this rule specifically prohibits any reference to 
controlled substances in pharmacy advertising, the Board had in-
terpreted this rule to prohibit the use of discount coupons toward 
the purchase of pseudoephedrine-containing products in Iowa. 
Following review and discussion of the rule, the Board has 
amended its previous interpretation of this rule as it relates to 
original manufacturer’s discount coupons for the purchase of 
controlled substances in Iowa. The Board has determined that, 
since the rule relates to pharmacy practices, the rule does not 
prohibit a manufacturer from offering or providing discount 
coupons for the manufacturer’s controlled substances products. 
Therefore, a pharmacy may honor a manufacturer’s original 
discount coupon presented by a patient for the purchase of a 
controlled substance including a pseudoephedrine-containing 
product. A coupon that is obtained online is acceptable. 
Pharmacists are reminded that when selling pseudoephedrine-
containing products, the quantity and time restrictions imposed 
by federal and state laws and regulations must still be complied 
with.
Board Calendar for 2012
The Board will hold regular Board meetings on the follow-
ing dates (all meetings will be held at the Board office in Des 
Moines, IA):
 ♦ June 26-28
 ♦ August 28-29
 ♦ November 7-8
Meeting agendas will be posted on the Board’s Web site. 
Dates are subject to change. Please contact the Board office at 
515/281-5944 to confirm meeting dates.
Board Web Site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and 
protects the public health, safety, and welfare through the ef-
fective regulation of the practice of pharmacy and the licensing 
of pharmacies, pharmacists, and others engaged in the sale, 
delivery, or distribution of prescription drugs and devices. Iowa 
Code §155A.2(1).
Follow the Board on Facebook and Twitter
Facebook  “Iowa Board of Pharmacy” 
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672  
Twitter  “IABoardPharmacy” 
http://twitter.com/#!/IABoardPharmacy
